Pierre Fabre

U-turn pivot about-face
Pharma

Atara, Pierre Fabre receive 2nd US rejection for Ebvallo

Atara didn't hold back in criticizing the FDA's rationale, noting that the regulator’s new point of view runs “contrary to the FDA’s prior guidance."
Fraiser Kansteiner Jan 12, 2026 11:30am
Photo of a chain being held together by a piece of rope

Atara hit with cell therapy clinical hold after FDA inspection

Jan 21, 2025 9:59am
FDA

Atara, Pierre Fabre hit a hurdle with Ebvallo in the US

Jan 16, 2025 9:36am
Pierre Fabre

Pierre Fabre commits up to $640M in T-cell deal with Atara

Nov 3, 2023 11:04am
buildings

French CMO Fareva adds 4 facilities, more than 1,000 employees

Nov 10, 2020 9:04am
puma

Is Puma off the M&A target list after Nerlynx licensing deal?

Apr 2, 2019 11:58am